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bacterial carrier DNA for small-cell-number
transcription factor ChIP-seq
Janus S Jakobsen1,2,3, Frederik O Bagger1,2,3,4†, Marie S Hasemann1,2,3†, Mikkel B Schuster1,2,3,
Anne-Katrine Frank1,2,3, Johannes Waage1,2,3,4,5, Kristoffer Vitting-Seerup4 and Bo T Porse1,2,3*Abstract
Background: Chromatin-Immunoprecipitation coupled with deep sequencing (ChIP-seq) is used to map
transcription factor occupancy and generate epigenetic profiles genome-wide. The requirement of nano-scale ChIP
DNA for generation of sequencing libraries has impeded ChIP-seq on in vivo tissues of low cell numbers.
Results: We describe a robust, simple and scalable methodology for ChIP-seq of low-abundant cell populations, verified
down to 10,000 cells. By employing non-mammalian genome mapping bacterial carrier DNA during amplification,
we reliably amplify down to 50 pg of ChIP DNA from transcription factor (CEBPA) and histone mark (H3K4me3)
ChIP. We further demonstrate that genomic profiles are highly resilient to changes in carrier DNA to ChIP DNA ratios.
Conclusions: This represents a significant advance compared to existing technologies, which involve either complex
steps of pre-selection for nucleosome-containing chromatin or pre-amplification of precipitated DNA, making them
prone to introduce experimental biases.
Keywords: ChIP-seq, Pico-scale, Histone mark, Transcription factor, Epigenetic profileBackground
Genomic mapping of histone modifications, their writers,
readers and erasers as well as transcription factors (TFs)
has become a house-hold approach to study the genome-
wide regulation of gene expression programs [1,2]. The
most widely applied method to generate such global map-
ping data is Chromatin ImmunoPrecipitation coupled
with high-throughput sequencing (ChIP-seq), which how-
ever generally requires millions of cells as input material
(e.g. [3]). Scarcity of cells in distinct, isolated in vivo popu-
lations such as phenotypically defined hematopoietic stem
and progenitor cells has thus hampered direct experimen-
tation on these. Examining such sub-populations is of in-
tense interest for the elucidation of mechanisms governing
lineage choice and commitment as well as transcriptional* Correspondence: bo.porse@finsenlab.dk
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unless otherwise stated.de-regulation in disease. Some researchers have cultured
harvested cells to achieve sufficient cell numbers and per-
formed ChIP-seq on cells undergoing differentiation in vitro,
but this approach can give rise to biases due to culture con-
ditions (e.g. [4]). Recent advances in the methodology have
demonstrated successful ChIP-seq on very limited cell num-
bers [5,6]. However, these techniques are impeded by add-
itional rounds of pre-amplification, potentially making them
prone to introduce artifacts. One of these methods was
established on cultured cells [6], while the other is limited to
showing ChIP-seq with antibodies against histone modifica-
tions [5], yielding significantly more immunoprecipitated
DNA than ChIP with antibodies to transcription factors.
Furthermore, the complexity and cost of pre-amplification
deters the implementation of the existing methods in many
laboratories. Another recent method uses an elegant step of
pre-ChIP indexing of Histone 3 containing chromatin frag-
ments, allowing downstream distinction of input material
[7]. The mixed inputs may thus function as mutual carriers
during single-tube, small cell number ChIP. Importantly, the
indexing step selects against nucleosome-poor genomical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jakobsen et al. BMC Genomics  (2015) 16:46 Page 2 of 12regions, making this approach less useful for unbiased
investigation of genome-wide TF occupancy.
Here, we describe a straightforward and versatile work-
flow for both transcription factor and histone mark ChIP-
seq on low abundance cell populations isolated directly
from the in vivo setting. A key element is the introduction
of bacterial carrier DNA at the amplification step. This
eliminates the previous need for pre-amplification and
makes possible robust generation of sequencing libraries
from picogram amounts of ChIP DNA.Results
Histone mark ChIP-seq of hematopoietic cell populations
The scarcity of biologically relevant in vivomaterial is often
barring global level investigations into normal development
as well as the aberrant regulation behind cancer and other
complex diseases. Of particular interest are the genome-
wide binding patterns of transcription factors and the asso-
ciated epigenetic profiles, which may pinpoint aberrant
molecular mechanisms underlying transcriptional dys-
regulation and development of disease. Here, we use a
standard FACS regimen (Additional file 1: Figure S1) to
isolate a specific hematopoietic GMP-blast population
from Cebpap30/p30 mice expressing a truncated variant of
the myeloid transcription factor CEBPA [8]. These mice de-
velop acute myeloid leukemia with complete penetrance,
and have been studied in detail [9-12]. However, the precise
molecular dysregulation driving leukemogenesis remains
obscure. We therefore developed a ChIP-seq assay compat-
ible with the numbers of isolated leukemic cells from the
in vivo context.Isolate specific cell 
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Figure 1 Generation of genomic coverage maps of DNA-associated p
small-scale ChIP-seq workflow, including pico-gram DNA quantification and
carrier-DNA in light grey.First, we optimized our ChIP protocol for small cell
numbers, which is described in detail here for clarity. Im-
mediately after the sorting procedure, isolated cells were
exposed to formaldehyde for cross-linking chromatin-
associated proteins to the DNA, washed and snap frozen
in liquid nitrogen. Next, they were subjected to sonica-
tion to break the chromatin into suitably sized fragments
(Figure 1 and Methods). We found that careful inspection
of the DNA size distribution of each batch of chromatin
was useful to prevent further processing of low quality
samples. This was achieved either by processing a parallel
sample of c-Kit enriched BM cells, providing a sufficient
cell number for standard gel electrophoresis, or by direct
inspection of each sample using the Bioanalyzer DNA1000
assay (Methods and (Additional file 2: Figure S2)). Chroma-
tin from roughly 125,000 cells, equivalent to 250–300 ng
of naked DNA, was used as input for each ChIP expe-
riment with antibodies against the histone marks H3
Lys27 trimethylation (H3K27me3) or H3 Lys4 trimethy-
lation (H3K4me3), performed in siliconized tubes with
optimized washing conditions and titrated antibody and
antibody-binding beads (Methods). Utilizing a thorough ap-
proach of extended protein degradation and de-crosslinking
steps, as well as phenol-chloroform extraction for retrieving
ChIP DNA ensured robust high recovery. This approach
allowed us to effectively enrich for genomic sequences asso-
ciated with either H3K27me3 or H3K4me3 as assessed by
quantitative PCR (qPCR) (Additional file 3: Figure S3). The
H3K27me3 ChIP produced ca. 2 ng of DNA for each sam-
ple. By making minor but important changes to the standard
Illumina protocol, we were able to consistently amplify the
2 ng ChIP DNA to generate libraries for high-throughputIsolate bound
DNA by ChIP
ChIP quality 
assessment, qPCR
Sequence and 
map to genome
Amplify using 
Illumina protocol
roteins from rare, isolated cell populations. Schematic depiction of
addition of fragmented bacterial DNA carrier. ChIP’ed DNA in black,
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amount of DNA below the effective range of standard ab-
sorbance or fluorescence assays. We circumvented this obs-
tacle by taking advantage of the fluorescence Nanodrop
instrument, which allows reliable detection of DNA down to
5 pg/ul in a 1 ul sample volume (Additional file 4: Figure S4).
With this approach, H3K4me3 ChIP DNA was mea-
sured to ca. 700 pg DNA, which we pooled to obtain the
2 ng sufficient for robust amplification (Methods). Using
the Illumina Hiseq platform, we deep sequenced two librar-
ies derived from two biologically independent samples for
each of the two histone marks (Additional file 5: Table S1).
We processed the aligned reads into genomic coverage pro-
files using standard procedures (Methods). Visual analysis
of the profiles suggested a good concordance with pre-
vious findings [5,13], showing enrichment of the H3K27me3
mark in gene bodies, intergenic regions as well as promoters
and H3K4me3 in gene promoter regions (Figure 2A). A
quantitative analysis mapped H3K27me3 reads as 6% in pro-
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Figure 2 Validation of small-scale ChIP-seq histone mark maps. (A) Tw
a 400 kb region on chromosome 4. (B) Genomic distribution of all mapped
methylation and mRNA expression in GMP-phenotype blast cells. Each data
comparisons of promoter read coverage (reads per kilobase) from two inde
TSS centered bins. Quantile normalized, 1/1 diagonal indicated by dashed
1 outlier pre-filtered). (E) SeqMiner cluster heatmaps showing signal intens
region centered on Refseq TSS positions.(intronic/exonic), while 21% of H3K4me3 reads resided
in promoters (Figure 2B). Promoter H3K4me3 modifica-
tions were positively and H3K27me3 negatively correlated
with activity of associated genes, as observed previously
(e.g. [5,13-17]) (Figure 2C). Finally, we assessed the repro-
ducibility of our ChIP-seq approach by comparing cover-
age in promoter regions from two biologically independent
replicates and found a high degree of correspondence, both
by visual inspection (example in Figure 2A and E) and
quantitative measures (Figure 2D). In the examined cell type,
we observe a near mutually exclusive pattern of H3K4me3
and H3K27me3 marks in promoters (Figure 2E), as opposed
to e.g. embryonic stem cells displaying a set of double-
marked promoters at poised genes, a hall-mark of the
undifferentiated state [18,19].
Transcription factor ChIP-seq of specific, isolated cell
populations
Chromatin-associated proteins with limited genomic dis-
tributions generally yield less ChIP DNA when compared)
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This is in line with our observations for H3K4me3 versus
H3K27me3 modifications, with characteristic peak-like
and broad distributions, respectively (e.g. [13]). Accord-
ingly, we expected transcription factor ChIP to yield even
less output DNA. To address this issue we used a larger
input cell number. We performed ChIP with antibodies
against CEBPA, a transcription factor known to be
expressed in the GMP blast population [10], using
chromatin from 250,000 or 500,000 cells, corresponding to
500–1000 ng input DNA per sample. By performing qPCR
for amplicons covering known CEBPA target sequences,
we verified the quality of the immuno-precipitation step
(Additional file 3: Figure S3). Utilizing the fluorescent
nanodrop, we measured the ChIP DNA yields of down to
250 pg (250,000 cells), an amount prohibitive for standard
use as a starting point for Illumina amplification.
We reasoned that an absolute loss during the amplifi-
cation procedure could be ameliorated by adding a DNA
carrier. First, we set out to test the use of a synthetic
120-mer oligo devoid of the terminal 3’-OH group,
which would prevent ligation to the amplification adap-
tors and hence preclude amplification during the PCR
step. This gave rise to unacceptable biases as displayed
by non-linear amplification of CEBPA enriched regions
(data not shown), probably due to low complexity of the
DNA pool during PCR amplification. We next hypothe-
sized that addition of complex carrier DNA that could
be amplified would be ideally suited to surpass this
problem. Hence, we performed an in silico mappability test
of 10 million 50-bp randomly extracted E. coli sequences,
of which 0 mapped to the mouse genome and 14457
(<0.15%) to the human counterpart (Additional file 6:
Additional Methods). Adding fragmented bacterial DNA
(1700 pg) to the CEBPA ChIP DNA (ca. 300 pg) produced
the 2 ng established to perform robustly in amplification.
By deep sequencing the resulting compound library, we
were able to map up to 20% of the obtained sequences to
the mouse genome (Additional file 5: Table S1). This corre-
sponded with the ratio between ChIP DNA and bacterial
carrier and typical ChIP-seq mapping frequencies.
CEBPA peaks were observed in promoter proximal
positions characteristic of many transcription factors
(e.g. [20]) (Figure 3A). Quantitative assessment of CEBPA
peak positions revealed a genomic distribution analogous
to a thoroughly validated CEBPA ChIP-seq dataset ob-
tained with liver cells (Figure 3B) [21]. Further visual
inspection identified several examples of CEBPA peaks
shared between hepatocyte and myeloid progenitor
data sets (Figure 3C). Strikingly, the two archetypical
homeostatic liver genes (Albumin (Alb) and Carbamoyl-
Phosphate Synthase 1 (Cps1)) displayed CEBPA peaks in
hepatocytes, but not in myeloid cells. Conversely, many
genes characteristic of the myeloid lineage displayedCEBPA peaks only in the myeloid ChIP-seq dataset (e.g.
Myeloperoxidase (Mpo), Colony stimulating factor 3 recep-
tor (Granulocyte)(Csf3r), Matrix Metallopeptidase 8
(Neutrophil Collagenase)(Mmp8), Selectin L(Sell), Col-
ony Stimulating Factor 2 (Granulocyte-Macrophage)
(Csf2), Fc Fragment of IgG, Low Affinity IIIb, Receptor
(Fcgr3)) (Figure 3C). Several of these are known CEBPA
targets. Two additional pieces of evidence supported
the validity and specificity of our CEBPA genomic oc-
cupancy data. Firstly, the top hit of a de novo motif
search in the enriched sequences matched the known
CEBPA binding logo (Figure 3D), and this motif was
found strongly enriched in the peak centers (Figure 3E).
Secondly, robust conservation in these sequences were
centered on CEBPA motifs, implying functional evolu-
tionary constrain (Figure 3F). Visual and quantitative
comparisons of coverage from two biologically inde-
pendent repeats indicated a high degree of reproduci-
bility (Figure 3A, G, H). Collectively, these data provide
evidence that transcription factor ChIP-seq on small-
cell-number populations is possible using bacterial
DNA as a carrier during the amplification step.
Amplification from picogram amounts of ChIP DNA
Many immunophenotypically defined hematopoietic com-
partments, e.g. the hematopoietic stem cells, consist of a
very limited number of cells. ChIP from small cell popula-
tions, as has been done previously by several groups
[3,5,6,22-24], consistently yield very limited quantities of
ChIP DNA. Hence, we wanted to investigate if our carrier
DNA amplification approach could be applied on pico-
gram-scale amounts of DNA. To test this, we generated a
series of compound DNA Illumina amplified libraries with
varying ratios of bacterial carrier DNA and ChIP DNA
from three pooled CEBPA ChIP samples (performed on
250,000 cells each) to allow direct comparisons between
libraries. Aiming to minimize the dilution ratio, some of
these libraries were generated using total input amounts
of 1000 or 500 pg. The resulting four libraries (CEBPA-3,
100 pg ChIP DNA and 1900 pg carrier; CEBPA-4, 100 and
900 pg; CEBPA-5, 100 and 400 pg; CEBPA-6, 50 and
450 pg), all displayed amplification output yields and size
distributions comparable to libraries generated from 2 ng
DNA (Additional file 7: Figure S5). High-throughput
sequencing of these libraries resulted in mapping fre-
quencies close to the expected based on standard ChIP-
seq mapping efficiency and ratios of ChIP DNA to bac-
terial carrier DNA. E.g. from a read number of roughly
85 million for CEBPA-5, 8.4 million mapped uniquely
to the mouse genome (Additional file 5: Table S1).
Visually, genomic coverage profiles for each of the four
new libraries closely matched our previous CEBPA tracks
(Figure 4A). An analysis of the degree of correlation be-
tween dilute libraries and CEBPA-1 indicated consistent,
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Figure 3 Validation of small-scale transcription factor ChIP-seq. (A) Profiles generated from 300 pg CEBPA ChIP-DNA. Region spanning a 100
kb region on chromosome 4. (B) Genomic distribution of top 26,713 CEBPA peaks (fold 30 cut-off) from GMP-blasts compared with 7,660 CEBPA
peak positions in hepatocytes (fold 30 cut-off, data from [21]), rounded numbers. (C) CEBPA coverage tracks from GMP-blast and hepatocyte gene
loci of shared, specific liver or myeloid cell expression. See text for full gene names. (D) De-novo motif search output from MEME (upper panel),
and top match JASPAR motif CEBPA (MA0102.2), both in logo format (lower panel). Data set as in D. (E) Distribution of the top match motif CEBPA
(MA0102.2, grey) in 200 bp regions centered on CEBPA-1 peak summits. USF1 (MA0093.1, purple) included for comparison. (F) Phylo-P conservation
plots in 100 bp (upper panel) and 600 bp (lower panel) regions centered on CEBPA-motifs in CEBPA-1 peaks. Green lines delineate motif position.
(G) Quantitative comparison of mean read coverage of two ChIP-seq repeats, CEBPA-1 and CEBPA-2, using CEBPA-1 peak regions defined by
MACS2. Quantile normalized, 1/1 diagonal indicated by dashed line (r = pearson correlation coefficient, calculated on normalized data,
1 outlier pre-filtered). MACS2 peak boundaries for CEBPA-1 (H) SeqMiner cluster heatmaps showing signal intensities for CEBPA-1 and CEBPA-2 profiles
in 10000 bp regions centered on peak summits. For F and G, peak set as in B.
Jakobsen et al. BMC Genomics  (2015) 16:46 Page 6 of 12high reproducibility (Figure 4B). Strikingly, the library
containing least ChIP DNA (CEBPA-6, 50 pg) display a
pearson correlation of 0.85 with the 300 pg CEBPA-1
library and overall recapitulate the genomic coverage of
this library (Figure 4B, C).
Next, we investigated the diluted libraries for presence
of CEBPA peaks at known CEBPA targets (e.g. Nuf2,
NDC80 kinetochore complex component, Smg-7 homolog,
nonsense mediated mRNA decay factor, CCAAT/enhancer
binding protein (C/EBP), alpha and - beta, prostaglandin-
endoperoxide synthase 2 and interleukin 6 receptor, alpha),
and found these in all coverage profiles (Figure 5A) [21].5
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in Figure 3B.To test our panel of libraries further, we performed qPCR to
quantify amplicons corresponding to the CEBPA enriched
regions mentioned above, which indicated reproducible and
practically uniform amplification across dilution ratios and
input amounts (Figure 5B).
ChIP-seq using 10,000 cells
To investigate if our methodology allows ChIP-seq on lim-
ited cell numbers, we transplanted a new cohort of mice
with the leukemic strain also used in the above and FACS-
isolated batches of 10,000 GMP-blasts. We optimized the
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Jakobsen et al. BMC Genomics  (2015) 16:46 Page 7 of 12material for the small-cell-number ChIP (Additional file 8:
Additional Protocols and Additional file 9: Figure S6).
Thorough optimization of ChIP conditions produced ro-
bust enrichments for histone mark (H3K4me3) as well as
TF (CEBPA) ChIP, both of which compared favorably to
ChIPs done according to a previously published 10,000 cell
ChIP methodology by Zwart et al. [24] (Figure 6A, B). The
major advance in the previous study was addition of a com-
bined mRNA/Histone carrier/blocker during the ChIP step.
We amended our protocol to include such a carrier, re-
sulting in even better enrichment as assessed by qPCR
(Figure 6A, B). A small amount of 10,000 cell ChIP-DNA
was used for examining enrichment and establishing
quantity, leaving ca. 60 pg DNA. Parallel generation ofsequencing libraries with and without bacterial carrier
demonstrated that at the 60 pg ChIP-DNA range, car-
rier is required for robust production of high-quality
Illumina libraries (Additional file 10: Figure S7). Both
visual inspection and quantitative analyses of genomic
coverage tracks from 10,000 cell ChIPs revealed good
correspondence with libraries generated from biologic-
ally independent higher-cell-number ChIPs (Figure 6C,
D, E). CEBPA-1 peaks were to a high degree shared
with a biological repeat (CEBPA −2), the diluted library
(CEBPA-6) and the low-cell-number ChIP (CEBPA-10K)
(Additional file 6: Additional Methods). Importantly, the
H3K4me3-10K profile generated from 60 pg ChIP-DNA,
which display substantially fewer mapped reads (Additional
file 5: Table S1), is highly similar to the H3K4me3-1 profile
from 2 ng DNA resulting from ChIP without using bac-
terial carrier for amplification (Figure 6C, D).
The recent establishment of the online Next Generation
Sequencing Quality Control (NGS-QC) Generator, a use-
ful cross-platform quality assessment tool [25], allowed a
quantitative comparison of our ChIP-seq approach with
already published methods (Additional file 6: Additional
Methods). Our methodology robustly produced NGS-QC
scores matching or exceeding those from previous ap-
proaches (Figure 6F and Additional file 11: Table S2).
Specifically, Shankaranarayanan (LinDA) amplification
[6] resulted in considerably lower NGS-QC scores at
the 10,000 cell range, while Adli amplification [5] and
the Zwart methodology [24] produced data sets with com-
parable scores for histone modification or transcription
factor ChIP-seq profiles, respectively (Figure 6F).
Discussion and conclusions
Here, we present a complete work-flow for ChIP-seq on
the limited cell populations of distinct in vivo cell com-
partments. By isolating a defined cell population with a
standard immunophenotypic sorting regimen and using a
rigorous and reliable ChIP approach, we were able to en-
rich regions marked by both broadly (H3K27me3) and
more narrowly (H3K4me3) distributed histone modifica-
tions as well as the precise regions defined by occupancy
of the central hematopoietic transcription factor, CEBPA.
Importantly, the fluorescence nanodrop instrument allowed
us to reliably measure the obtained picogram amounts of
ChIP DNA. We demonstrate that these amounts of ChIP
DNA could be faithfully amplified to generate libraries for
Illumina sequencing by addition of fragmented E. coli car-
rier DNA. Further, we show the resulting coverage profiles
to match previous data for the actively transcribed gene
associated (H3K4me3) and repressed gene associated
(H3K27me3) histone marks, and to specifically recover
known myeloid specific CEBPA target regions. We provide
evidence that CEBPA bound regions from a pool of ChIP’ed
DNA down to 50 pg are amplified in a linear manner with
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Figure 6 10,000 cell histone mark and transcription factor ChIP-seq. (A and B) ChIP using 10,000 sorted GMP-blasts as input. Our protocol
(Jakobsen) with and without mRNA/Histone carrier, compared to the Zwart protocol. qPCR assessment of enrichment ratios, n = 4-6, error bars
show SD. *** = P < 0.001, T-test, Holm-Sidak correction for multiple testing. (A) H3K4me3-ChIP, ratios are amplicon Smc4 versus the negative Sfi3.
(B) CEBPA-ChIP, ratios are amplicon Ptgs2 versus the negative Sfi3. (C) H3K4me3 and CEBPA ChIP-seq profiles across a region spanning a 130 kb
region on chromosome 2, using 375,000 (H3K4me3-1) or 10,000 (H3K4me3-10 K) cells as input (two upper tracks) and CEBPA ChIP-seq profiles of
using 250,000 (CEBPA-1) or 10,000 (CEBPA-10 K) cells as input (two lower tracks). (D) Quantitative comparisons of mean read coverage of
H3K4me3-1 versus H3K4me3-10 K (left panel) and CEBPA-1 versus CEBPA-10 K (right panel). All settings as described above. (E) Peak overlaps
between ALPHA-1 and ALPHA-2, CEBPA-6 and CEBPA-10 K. MACS2 peaks were ranked for FDR (q-values) and the CEBPA-1 top 1% set tested
against peaks scoring FDR < 10−5, in the FDR top 1% or in top 10,000. (F) Schematic bar diagram depicting summed NGS-QC (Next Generation
Sequencing – Quality Check) score for each of the listed small-scale ChIP-seq data sets. Listed is number of cells used as input material, source
of material (TC: tissue culture cells, IV: in vivo cells) and antibody target (HM: histone mark, TF: transcription factor). The ChIP-DNA fraction
column denotes amplification of a fraction of DNA from a higher-cell-number ChIP corresponding to the indicated number of cells. The carrier
column indicates use of mRNA/Histone as carrier during the ChIP procedure (Y = yes). All scores represent best replicate. NGS-QC sum score is
calculated as a sum of quartile scores (best = 4, worst = 1) for read sub-sampling of 90, 70 and 50% of total mapped reads.
Jakobsen et al. BMC Genomics  (2015) 16:46 Page 8 of 12our technique. Finally, we demonstrate that our straight-
forward methodology can produce high-quality ChIP-seq
coverage tracks from as little as 10,000 isolated in vivo cells
using antibodies against histone mark (H3K4me3) as well
as transcriptional factor (CEBPA) antibodies. Importantly,
the H3K4me3-ChIP 10,000 cell genomic coverage profile is
very similar to the profiles generated without bacterial car-
rier (H3K4me3-1/-2), indicating that the addition of
bacterial carrier does not impede amplification or Illu-
mina sequencing.
Our methodology can be used to elucidate important
biological circuitries at a global level. For instance, we
can clearly detect differences of direct targets of CEBPAin specific cell types as illustrated in Figure 3. Importantly,
two recently published studies demonstrate the usefulness
of our approach by revealing molecular mechanisms be-
hind initiation of acute myeloid leukemia and regulation
of hematopoietic stem cells [26,27]. Furthermore, our
technology should combine easily with other genomics
approaches, for instance Chia-PET [28], to permit gen-
eration of libraries from otherwise prohibitively small
amounts of DNA.
Other available methodologies that allow generation
of ChIP-seq data from limited amounts of input mater-
ial rely on an extra amplification step, based either on cus-
tom designed random primers or T7 RNA-polymerase
Jakobsen et al. BMC Genomics  (2015) 16:46 Page 9 of 12technology [5,6]. Even as these methods are very useful,
introducing extra and complex steps in the amplification
procedure will inevitably increase the risk of errors, and is
costly and time-consuming. Our method is based on the
conceptually simple addition of non-mapping DNA as car-
rier and should as such be easy to implement in any
laboratory that already performs Illumina platform
ChIP-seq.
A disadvantage of our approach is the added cost of se-
quencing E. coli DNA, generating data that will be dis-
carded. This drawback increases with the ratio between
bacterial and ChIP DNA, i.e. as fewer cells are used or less
material recovered, for example as a result of poor anti-
bodies or low expression of the ChIPed factor. We have
tried to address this issue by demonstrating the feasi-
bility of using just 500 picogram total input material
for the amplification procedure. The steady decline of se-
quencing prices should also help reduce this disadvantage.
Several groups have optimized ChIP from very small cell
numbers (e.g. [3]), whereas our study focusses on refining
the amplification step of ChIP-seq. Some reports have
shown the addition of carrier chromatin during the ChIP
stage to facilitate the application on small cell numbers,
but these methodologies are either not tested or incom-
patible with high-throughput sequencing [29]. Recently,
Zwart et al. demonstrated an increase in the ChIP-seq sig-
nal to noise ratio by adding carrier consisting of RNA and
histones [24]. While ChIP protocols generally include bo-
vine serum albumin as a carrier (e.g. [30]), Zwart and co-
workers speculate that combined oligonucleotide RNA
and histones mimic chromatin better, and hence offer im-
proved blocking of spurious binding. Both components
are degraded prior to the amplification step, making the
modification suitable for use in ChIP-seq. We compare a
low-cell-number optimized version of our methodology
and find it to surpass the Zwart approach for the tested
antibodies (Figure 6A, B). Nevertheless, adopting the
mRNA/histone ChIP level carrier considerably improves
our protocol (Figure 6A, B), clearly demonstrating the
value of the Zwart at al. contribution to the development
of ChIP technology.
In summary, our study, in combination with the pro-
gress of sequencing technology, makes possible rela-
tively straight-forward ChIP-seq even on very scarce
cell numbers e.g. from stem cell populations. This opens
the door for extensive genome-wide investigation of the
regulatory circuitries at all differentiation levels of in vivo
tissues.Methods
Additional methods and protocols in additional files
(Additional file 6: Additional Methods and Additional
file 8: Additional Protocols and Buffer Recipes).Mouse work
Blast-GMP populations were generated as described pre-
viously [31]. Briefly, fetal livers were isolated from E14.5
Cebpa p30/p30 (CD45.2) female embryos, homogenized
and filtered through a 70 um filter. Each liver was trans-
planted into four lethally irradiated recipients (CD45.1)
by tail vein injection. The recipients developed acute
myeloid leukemia (AML) within 9–11 months after
transplantation and sacrificed when moribund. The bone
marrow (BM) was isolated and retransplanted into sub-
lethally irradiated recipients (1.5 × 10^6 whole BM cells/
recipient). The procedure was repeated to generate a ter-
tiary leukemia, from which whole BM was retrieved for
isolation of GMP-blasts. Genotyping was performed as
previously described [10], utilizing genomic tail DNA as
template. All mouse work was performed according to na-
tional and international guidelines and approved by the
Danish Animal Ethical Committee under license #2012-
15-2934-00725.
Flow cytometry and purification of hematopoietic
progenitor populations
BM cells were isolated and stained using the following anti-
bodies: CD41-FITC, CD105-PE, Gr-1- PECy5, B220-PECy5,
CD3-PECy5, Sca1-PerCp5.5, Ter119-PECy7, CD16/CD32-
Alexa Flour 700, c-Kit APC-Alexa 750, CD45.2-Biotin,
CD45.1-eFlour450 (all from eBioscience), Mac1-PECy5 (BD
Biosciences), Streptavidin-QD655 (Invitrogen), CD150-APC
(BioLegend), and 7-AAD (Invitrogen) as viability marker.
For sorting, cells were c-Kit enriched using CD117 microbe-
ads and MACS LS separations columns (Miltenyi Biotec)
prior to staining. GMP-blasts used in this study were defined
as previously described [8,10] (Additional file 1: Figure S1).
Chromatin preparation
GMP-blasts were sorted into pre-wetted siliconized micro-
centrifuge tubes (Biozym, cat#1267-2970) on ice, containing
300 μl PBS and 3% Fetal Calf Serum (FCS) (Saveen &
Werner, cat#FB-1090/500). Volume was adjusted to 1.4 ml
with cold PBS-3% FCS and samples cross-linked in 1% for-
maldehyde for 10 minutes at room temperature using a ro-
tator. Cross-linking was quenched using 0.125 M Glycine
and samples washed twice in cold PBS-3% FCS using a
swinging bucket centrifuge (4 minutes, 600 g) and soft spin
settings to minimize material loss. Cells were lysed as de-
scribed previously in 300 μl lysis buffer [21], applying up/
down pipetting 10 times using a 100 ul tip low retention
tip. Samples were sonicated using a Bioruptor sonicator
plus for 30 cycles, 15/30 seconds on/off, high setting,
and debris pelleted by centrifuging cold at 14,000 g for 10
minutes. Fragmentation of chromatin was evaluated on ex-
tracted DNA using either: 1) a c-Kit enriched 500,000 cell
sample (see above) processed in parallel (one of six tubes
sonicated simultaneously) and agarose gel electrophoresis
Jakobsen et al. BMC Genomics  (2015) 16:46 Page 10 of 12or, 2) direct sample size inspection of a 20 ul aliquot
using a Bioanalyzer (Agilent DNA1000 kit cat#5067-
1504) (Additional file 2: Figure S2). Output quantity was
determined for each sample using the Qubit instrument
(Invitrogen, HS-assay cat#Q32851).
Chromatin Immunoprecipitation
ChIP was performed essentially as described previously
with ca. 125,000 cells for histone mark and ca. 250,000 cells
for CEBPA ChIP [30]. Quanta of used antibodies (CEBPA,
Santa Cruz sc-61, lot#J0407, 0.2 ug; H3K27me3, Cell signal-
ing #9733S, lot#2, 1 ul; H3K4me3, Cell signaling #9751S,
lot#2, 1 ul) and protein A beads (Sigma, cat#P9424 , 10 ul
50%/50% beads/RIPA-low salt (140 mM)) were optimized
for low input amounts, using siliconized tubes (Biozym,
cat#1267-2970). Preincubation was performed with 10 ul of
bead-slurry to minimize background. Washing conditions
and buffers as in [30], but with 5 minute, 500 μl washes;
2× RIPA-low salt (140 mM NaCl) and 2× RIPA-high salt
(500 mM NaCl) for CEBPA ChIP and 1× RIPA-low salt
and 3× RIPA-high salt for the histone mark antibodies, re-
placing previous RIPA buffer washes. Retrieval of immune-
precipitated DNA was optimized using overnight pro-
teinase K treatment and 6-hour 65°C de-crosslinking
with phenol-chloroform (cat#9732) extraction in pha-
selock tubes (5-prime, cat#713-2536) to Lo-Bind tubes
(Eppendorf, cat#525-0130) as described [30]. Pico-scale
ChIP DNA concentrations were determined using the
fluorescent Nanodrop 3300 PicoGreen assay (Thermo-
Scientific and Invitrogen, cat#p7589) (Additional file 4:
Figure S4). Quantitative PCR (qPCR) for ChIP validation
was performed on a Roche Lightcycler 480 with primers
amplifying known CEBPA target sequences or regions ex-
pected to be marked by the H3K4me3 or H3K27me3
histone modifications, comparing to predicted negative re-
gions. Primers and ChIP enrichments are found in additio-
nal files (Additional file 12: Table S3 and Additional file 3:
Figure S3). Full protocol and buffer recipes are included in
additional files (Additional file 8: Additional Protocols and
Buffer Recipes).
Preparation of libraries from nano- and picogram input
DNA
Amplification of 2 ng ChIP DNA was essentially performed
as described by the manufacturer (NEB, cat#E6240S), with
the use of precast 2% SYBR agarose gels (Invitrogen,
cat#G5218-02) and excision of band size 175–400 bp. Key
modifications consisted of a 30 minute ligation step, 30 mi-
nute gel solubilization at 37°C of excised gel fragments, and
a prolonged, double run-through elution step (each three
minutes) with preheated (55°C) elution buffer for all
column purifications (Qiagen, cats#28104,28704,28004)
to ensure robust recovery. Amplification of picogram
precipitated DNA was performed by adding carrier upto a total of 500 pg, 1000 pg or 2 ng as indicated using
purified, chromosomal E. coli DNA, sonicated to a size
distribution of 200–500 bp (Diagenode current proto-
cols). All steps were performed in Lo-Bind tubes
(Eppendorf, cat#525-0130). Libraries were generated for
duplex or triplex sequencing using a NEB kit (cat#E7335S),
and size distributions assessed by Bioanalyzer (Agilent,
High Sensitivity kit, cat#5067-4626), (Additional file 7:
Figure S5 and Additional file 10: Figure S7). Full protocol
included in additional files (Additional file 8: Additional
Protocols and Buffer Recipes).Sequencing and mapping
All libraries were single-end sequenced on the Illumina
HiSeq2000 platform at the Danish National High-throughput
DNA Sequencing Centre. The resulting 50-mer reads
were mapped to the NCBI7/mm9 (Mus musculus) gen-
ome assembly using Bowtie v. 0.12.8 with standard set-
tings for unique mapping [32]. An overview of sequencing
and mapping statistics is presented in (Additional file 5:
Table S1). See additional files for mapping of bacterial
carrier sequences (Additional file 6: Additional Methods).Visualization, statistical analysis and validation of profiles
Bigwig files for UCSC genome coverage visualization were
generated using Samtools [33,34], Bedtools [35], and UCSC
wigtobigwig [36]. All coverage heatmaps were built using
SeqMiner [37]. Histone mark profiles were examined at
transcription start site (TSSs) regions (1000 bp) based on
RefSeq longest isoform gene positions [38], excluding non-
coding and mitochondrial genes. Peakcalling was per-
formed using MACS2, with parameter “–to-large” [39]. A
hematopoietic progenitor IgG mock ChIP-seq data set
of 31,088,767 mapped reads was used as reference [27].
CEBPA-1 peak regions for analysis were defined by
MACS2 cut-off of fold 30, q-value 50. For comparisons,
CEBPA-1 and −2/-3/-4/-5/-6 coverages were normal-
ized to mapped read depth. De novo motif search was
performed with MEME-ChIP online using CEBPA-1
200 bp peak regions centered on summits [40]. Cen-
trimo was used for distribution analysis of enriched
motifs [41]. See additional files for genomic position
annotations of reads and peaks, ChIP track coverage/
gene expression correlations and CEBPA-1 peak region
Phylo-P conservation analysis (Additional file 6: Additional
Methods).Availability of supporting data
Supporting data is included in Additional files 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12 and 13 and at NCBI Gene Expression
Omnibus (GEO), entry: GSE55850.
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Additional file 1: Figure S1. Schematic representation of fluorescence
activated cell sorting strategy. This is a depiction of the FACS gating
regimen used. Detailed description is provided within the file.
Additional file 2: Figure S2. Validation of sonicated input chromatin. A
demonstration of gel-electroforetic and Bioanalyzer analyses of input
chromatin DNA size distribution. Detailed description is provided within
the file.
Additional file 3: Figure S3. Assessment of individual sample ChIP
enrichment. This is a figure showing qPCR validation of ChIP enrichments
prior to library generation. Detailed description is provided within the file.
Additional file 4: Figure S4. Measuring picograms of DNA with the
fluorescence Nanodrop 3300. A figure depicting fluorescent nanodrop
measurement linearity and reproducibility in the 5–400 pg range.
Detailed description is provided within the file.
Additional file 5: Table S1. Sequencing and mapping statistics.
Detailed description is provided within the file.
Additional file 6: Additional methods. This document is a description
of additional methods including mapping of bacterial carrier DNA,
genomic annotation of peaks/mapped reads, promoter coverage
correlation with gene expression and conservation analysis.
Additional file 7: Figure S5. Size distributions of amplified ChIP-DNA
libraries. Libraries assessed by Bioanalyzer analysis. Detailed description is
provided within the file.
Additional file 8: Additional protocols. This contains detailed
protocols for small-scale ChIP, amplification methodology and buffer
recipes.
Additional file 9: Figure S6. Validation of sonicated input chromatin
size distribution from limited cell numbers. Detailed description is
provided within the file.
Additional file 10: Figure S7. Illumina sequencing libraries done with
or without bacterial carrier. Detailed description is provided within the file.
Additional file 11: Table S2. List of comparable low-cell number
datasets with NGS-QC scores. Detailed description is provided within
the file.
Additional file 12: Table S3. List of primer sets used. Sequences of all
primers used for this study.
Additional file 13: Additional references. This is a list of references
used in additional methods and protocols.Abbreviations
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